Biohaven’s migraine drug NURTEC™ ODT receives FDA approval
Category: #health  By Pankaj Singh  Date: 2020-02-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biohaven’s migraine drug NURTEC™ ODT receives FDA approval

A clinical-stage biopharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd. recently announced that the FDA has approved NURTEC™ ODT, which has been developed for the acute treatment of migraine in adults. The drug is the first FDA approved product of Biohaven, which is focused upon advancing innovative therapies for neurological diseases.

Consumption of a quick-dissolving NURTEC ODT (rimegepant) tablet can provide fast pain relief and aid patients to function normally within an hour. The drug delivers prolonged efficacy that lasts up to 48 hours for most of the patients. However, rimegepant is not meant for the preventive treatment of migraine. Biohaven is expecting favorable results from its prevention of migraine trial in the coming months.

Vlad Coric, M.D. and CEO of Biohaven Pharmaceutical Holding was reportedly quoted saying that the approval of NURTEC ODT by FDA marks an important milestone for the migraine community and is also a transformative event for the company. Millions of people who are suffering from migraine are not satisfied with their current acute treatment because of the significant tradeoffs; reduced ability to function and troublesome side effects.

NURTEC ODT can be considered an important novel oral acute treatment for migraine that has the potential to instantly reduce and eliminate pain as well as aid patients to get back to their lives normally.

Coric added saying that NURTEC ODT will be the first of many innovative medicines created by the company to become available to treat dreadful neurological diseases, a therapeutic category many other companies have neglected. He further added that Biohaven is dedicated to helping patients with such conditions, who often have limited/no treatment options, to live better and more productive lives.

With quick-dissolve oral tablet formula, NURTEC ODT works by blocking CGRP receptors (a G-protein-coupled receptor of the B subtype), thereby treating the roots of migraine. The drug is not narcotic or opioid, does not have addiction potential and is not scheduled as a controlled substance by the United States Drug Enforcement Administration.  

Source Credit: https://www.prnewswire.com/news-releases/biohavens-nurtec-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults-301013021.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...